This site is intended only for healthcare professionals resident in Egypt 




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact Us



Clinical Information Clinical Information Burden of meningococcal disease Serogroup distribution Nimenrix® immunogenicity Nimenrix® persistence Nimenrix® dose and administration Real-world impact Summary Important Safety Information Abbreviated Prescribing Information Support and Services Support and Services VideosWebinarsMaterialsSelf-detail Presentations

Important Safety Information2

Therapeutic indications:
Nimenrix® is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y.1

Dosage and administration:
Nimenrix® should be used in accordance with available official recommendations.

Primary immunization:
Infants from 6 weeks to less than 6 months of age:

Two doses, each of 0.5 ml, should be administered with an interval of 2 months between doses.

Infants from 6 months of age, children, adolescents and adults:
A single 0.5 mL dose should be administered.1  

Booster doses:
Long-term antibody persistence data following vaccination with Nimenrix® are available up to 10 years after vaccination. After completion of the primary immunisation course in infants 6 weeks to less than 12 months of age, a booster dose should be given at 12 months of age with an interval of at least 2 months after the last Nimenrix® vaccination. In previously vaccinated individuals 12 months of age and older, Nimenrix® may be given as a booster dose if they have received primary vaccination with a conjugated or plain polysaccharide meningococcal vaccine.1

Hypersensitivity to the active substances or to any of the excipients.1

Special Warnings and precautions for use:
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded. Nimenrix® should under no circumstances be administered intravascularly, intradermally or subcutaneously. It is good clinical practice to precede vaccination by a review of the medical history (especially with regard to previous vaccination and possible occurrence of undesirable effects) and a clinical examination. Appropriate medical treatment and supervision should always be readily available in case of a rare anaphylactic event following the administration of the vaccine.1

Intercurrent illness
Vaccination with Nimenrix® should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination.1

Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. It is important that procedures are in place to avoid injury from faints.1

Thrombocytopenia and coagulation disorders
Nimenrix® should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an intramuscular administration to these subjects.1

Adverse reactions:
Very common adverse reactions are appetite lost, irritability, drowsiness, headache, fever, redness, pain and swelling at injection site and fatigue.1

Find out moreLoading
Find out moreLoading
Find out moreLoading
  1. Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777-779.
  2. Nimenrix (Meningococcal group A, C, W-135 and Y conjugate vaccine). Egyptian Drug Authority leaflet approval date: 19/10/2022 Revision date: May 2022.
Click here for Nimenrix® Prescribing Information Loading

Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025


Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 

Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.

For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No
You are leaving the Pfizer for Professionals website
​You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.
You are leaving the Pfizer for Professionals website You are being directed to a third-party website.

Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable.